



JC02 Rec'd PCT/PTC 15 AUG 2005

PCT
#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: FISHMAN =14A

In re Application of:) Conf. No.: 1479
Pnina FISHMAN et al)
Appln. No.: 10/529,650) Art Unit:
Filing Date: February 24, 2005)
371(c) Date: March 31, 2005) Examiner:
For: TREATMENT OF) Washington, D.C.
HYPERPROLIFERATIVE DISEASE) August 15, 2005

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office,

either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. Other information being provided for the examiner's consideration follows:


International Search Report

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Jay M. Finkelstein
Registration No. 21,082

:jaa

G:\bn\c\cohn\fishman14A\pto\IDS 15au05.doc
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528



AUG 15 2015

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sh

1

of

Complete if Known

Application Number	
Filing Date	March 31, 2005
First Named Inventor	Pnina FISHMAN et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	FISHMAN =14A

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

Complete if Known

Application Number	
Filing Date	march 31, 2005
First Named Inventor	Pnina FISHMAN et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	FISHMAN =14A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	AC	ANDINO, Raul, "RNAi puts a lid on virus replication", Nature Biotechnology. (June 2003). 21(6):629-630.
	AD	CARMICHAEL, Gordon, "Silencing viruses with RNA". Nature. (July 25, 2002). 418:379-380.
	AE	DIXON, Alstair, "Tissue distribution of adenosine receptor mRNAs in the rat", British Journal of Pharmacology. (1996).. 118:1461-1468.
	AF	FISHMAN, Pnina, et al, "A3 adenosine receptor as a target for cancer therapy", Anti-Cancer Drugs. (2002). 13:4370443.
	AG	FISHMAN, Pnina, et al, "An agonist to the A ₃ adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 β and NF- κ B", Oncogene. (2004). 23:2465-2471.
	AH	GESSI, Stefania, et al, "A ₃ adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study", Molecular Pharmacology. ((2002). 61:415-424.
	AI	GITLIN, Leonid, et al, "Short interfering RNA confers intracellular antiviral immunity in human cells", Nature (May 8, 2003). 423:430-434.
	AJ	JACQUE, Jean-Marc, "Modulation of HIV-1 replication by RNA interference", Nature. (25 July 2002). 418:435-438.
	AK	MADI, Lea, et al, "A3 Adenosine receptor activation in melanoma cells", The Journal of Biological Chemistry. (October 24, 2003). 278(43): 42121-42130.
	AL	MADI, Lea, et al, "A3 adenosine receptor activation in melanoma cells: Association between receptor fate and tumor growth utilizing siRNA", International Journal of Molecular Medicine. (2003). 12(Suppl1):S42. Abstract 251:8 th World Congress on advances in Oncology and 6 th International Symposium on Molecular Medicine, Crete, Greece, October 16-18, 2003.
	AM	MERIGHI, Stefania, et al, "Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line", British Journal of Pharmacology. (2001). 134:1215-1226.
	AN	MERIMSKY, Ofer, et al, "Modulation of the A ₃ adenosine receptor by low agonist concentration induces antitumor and myelostimulatory effects", Drug Development Research, (2003). 58:386-389.
	AO	OHANA, G, et al, "Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101", British Journal of Cancer. (2003). 89:1552-1558.
	AP	SUH, Byung-Chang, et al, "Pharmacological characterization of adenosine receptors in PGT- β mouse pineal gland tumour cells", British Journal of Pharmacology. (2001). 134:132-142.

Examiner Signature		Date Considered
--------------------	--	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.